Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion type Assertion NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_head.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion description "[The treatment of NB cells with metformin or MIBG resulted in an increased expression of genes encoding biomarkers for favorable outcome in NB [(ephrin (EFN)B2, EFNB3, EPH receptor B6 (EPHB6), neurotrophic tyrosine kinase, receptor, type 1 (NTRK1), CD44 and Myc-interacting zinc finger protein (MIZ-1)] and tumor suppressor genes [(early growth response 1 (EGR1), EPH receptor A2 (EPHA2), growth arrest and DNA-damage-inducible, beta (GADD45B), neuregulin 1 (NRG1), TP53 apoptosis effector (PERP) and sel-1 suppressor of lin-12-like (C. elegans) (SEL1L)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_provenance.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion evidence source_evidence_literature NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_provenance.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion SIO_000772 24190252 NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_provenance.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion wasDerivedFrom befree-2016 NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_provenance.
- NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_assertion wasGeneratedBy ECO_0000203 NP1124957.RA_lASK8i9q6ghr52WXnzW7wWotTuhlsPh5ppympY__9c130_provenance.